---
id: "2026-09-10-insilico-rentosertib-phase-3"
url: "https://postcutoff.com/e/2026-09-10-insilico-rentosertib-phase-3/"
as_of: "2026-11-13T13:49:00+01:00"
date: "2026-09-10"
date_precision: day
category: science
importance: 4
confidence: high
status: [Event confirmed, Awaiting review]
verification: Peer-reviewed
sources: 6
editor: human editor
human_review: null
version: "2026-10-07"
---

As of: 2026-11-13 13:49 CET.
Researched and written by AI agents (Claude Opus 5.5 in Claude Code), with a human editor. How we work: https://postcutoff.com/about/
Canonical page: https://postcutoff.com/e/2026-09-10-insilico-rentosertib-phase-3/

# First Phase III trial of a generative-AI-discovered drug doses first patient

Full title: First Phase III trial of a generative-AI-discovered drug doses first patient (Insilico's rentosertib)

On 2026-09-10 Insilico Medicine dosed the first patients in GENESIS-IPF-3, billed as the world's first Phase III trial of a drug whose target and molecule were discovered with generative AI: rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis, tested in 320 patients at 47 Chinese centers over 52 weeks.

## Key facts
- First patients dosed 2026-09-10 at Peking Union Medical College Hospital and Shanghai Pulmonary Hospital
- Randomized, double-blind, placebo-controlled; 320 participants; 47 centers in China; once daily for 52 weeks
- Primary endpoint: annual rate of FVC decline over 52 weeks; key secondary: time to first disease-progression event
- Phase IIa (Nature Medicine, 2025): 60 mg QD arm showed mean FVC +98.4 mL at 12 weeks, dose-dependent trend
- Mechanism: TNIK inhibition (target also identified by Insilico's AI platform)
- Pipeline context: on 2026-01-23 the FDA cleared Insilico's IND for ISM8969, an oral brain-penetrant NLRP3 inhibitor for Parkinson's disease discovered and optimized with its Chemistry42 generative-chemistry engine (Phase I in healthy volunteers; co-developed 50/50 with Hygtia Therapeutics, which also won China NMPA IND clearance)

## What happened

Insilico's rentosertib is the furthest-advanced drug in which both the target and the molecule came from generative AI. Phase III is the final stage before regulatory approval.

## Why it matters

If positive (results likely 2027+), it would be the first approved generative-AI-discovered drug — the key proof point for AI drug discovery's promise to cut time and cost.

## What is disputed or not yet verified

- Verification: Phase IIa trial results peer-reviewed in Nature Medicine (June 2025); Phase III efficacy not yet shown

## Your AI and this story

- GPT-6 Astra (training cutoff April 2026): 133 days after its cutoff
- Claude Opus 5.5 (training cutoff June 2026): 72 days after its cutoff
- Gemini 4 Hydrogen (training cutoff March 2026): 163 days after its cutoff
- Grok 4.7 (training cutoff May 2026): 102 days after its cutoff

## Sources

1. [Insilico: first patient dosed in GENESIS-IPF-3](https://insilico.com/news/isn1009261-insilico-medicine-doses-first-patient-genesis-ipf-3) (insilico.com, official)
2. [PR Newswire: Insilico initiates Phase III trial for rentosertib](https://www.prnewswire.com/news-releases/insilico-initiates-phase-iii-clinical-trial-for-rentosertib-its-ai-empowered-tnik-inhibitor-for-idiopathic-pulmonary-fibrosis-302819553.html) (prnewswire.com, official)
3. [Insilico: IND approval from FDA for ISM8969 (Jan 23, 2026)](https://insilico.com/news/az7xmeem81-insilico-medicine-receives-ind-approval) (insilico.com, official)
4. [EurekAlert: Nature Medicine publishes rentosertib Phase IIa results (June 2025)](https://www.eurekalert.org/news-releases/1086096) (eurekalert.org, press)
5. [Drug Target Review: Insilico begins Phase III of AI-designed drug](https://www.drugtargetreview.com/insilico-medicine-launches-phase-iii-trial-of-ai-designed-rentosertib-drug/2135890.article) (drugtargetreview.com, press)
6. [EurekAlert: ISM8969/HT-001 receives NMPA IND clearance](https://www.eurekalert.org/news-releases/1138579) (eurekalert.org, press)

## Changes

- 2026-10-07: Science block: kind: other (not a long-open problem; listed with other AI science results, not in the open-problems count); verification reworded: only the Phase IIa results are peer-reviewed, Phase III efficacy is not yet shown
- 2026-10-04: Added ISM8969 FDA IND clearance (Jan 2026) as pipeline context; too routine for its own entry
- 2026-09-29: Added science block (science & math tab)
- 2026-09-29 (filed): Created